两种三唑类抗真菌剂（伏立康唑[UK-109,496]和氟康唑）对念珠菌属的体外研究。
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.
作者信息
Barry A L, Brown S D
机构信息
Clinical Microbiology Institute, Tualatin, Oregon 97062, USA.
出版信息
Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.
Abstract
A new triazole derivative (voriconazole or UK-109,496) and fluconazole were tested against 249 isolates of Candida spp. representing six species. Voriconazole was 10 to 100 times more potent than fluconazole. Strains with decreased susceptibility to fluconazole were inhibited by relatively low concentrations of voriconazole.
摘要
一种新的三唑衍生物（伏立康唑或UK-109,496）和氟康唑针对代表6个种的249株念珠菌属分离株进行了测试。伏立康唑的效力比氟康唑强10至100倍。对氟康唑敏感性降低的菌株被相对低浓度的伏立康唑所抑制。
相似文献
1
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.
Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.
2
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
Antimicrob Agents Chemother. 1997 Nov;41(11):2492-6. doi: 10.1128/AAC.41.11.2492.
3
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.
4
The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells.
J Chemother. 1998 Feb;10(1):7-16. doi: 10.1179/joc.1998.10.1.7.
5
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Antimicrob Agents Chemother. 1998 Jan;42(1):161-3. doi: 10.1128/AAC.42.1.161.
6
Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
J Clin Microbiol. 2007 Jan;45(1):70-5. doi: 10.1128/JCM.01551-06. Epub 2006 Nov 1.
7
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rev Esp Quimioter. 2003 Jun;16(2):227-32.
8
In vitro activity of voriconazole against Candida species.
Diagn Microbiol Infect Dis. 1998 May;31(1):297-300. doi: 10.1016/s0732-8893(98)00005-4.
9
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
Antimicrob Agents Chemother. 1997 Mar;41(3):575-7. doi: 10.1128/AAC.41.3.575.
10
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.
引用本文的文献
1
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.
Adv Drug Deliv Rev. 2023 May;196:114776. doi: 10.1016/j.addr.2023.114776. Epub 2023 Mar 17.
2
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
3
Voriconazole-induced periostitis: a new rheumatic disorder.
Clin Rheumatol. 2017 Mar;36(3):609-615. doi: 10.1007/s10067-016-3341-7. Epub 2016 Jul 4.
4
Invasive fungal infections in the ICU: how to approach, how to treat.
Molecules. 2014 Jan 17;19(1):1085-119. doi: 10.3390/molecules19011085.
5
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Antimicrob Agents Chemother. 2007 Jan;51(1):137-43. doi: 10.1128/AAC.00957-06. Epub 2006 Nov 6.
6
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
J Clin Microbiol. 2006 Mar;44(3):819-26. doi: 10.1128/JCM.44.3.819-826.2006.
7
Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
J Clin Microbiol. 2003 Nov;41(11):5270-2. doi: 10.1128/JCM.41.11.5270-5272.2003.
8
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
J Clin Microbiol. 2003 Jan;41(1):78-83. doi: 10.1128/JCM.41.1.78-83.2003.
9
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.
Antimicrob Agents Chemother. 2002 Sep;46(9):3091-3. doi: 10.1128/AAC.46.9.3091-3093.2002.
10
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8. doi: 10.1128/AAC.46.8.2564-2568.2002.
Zotero 插件